Skip to main content
. 2016 Sep 23;7(43):70654–70668. doi: 10.18632/oncotarget.12203

Figure 2. Prognostic significance of serum ApoA-1 levels of HCC patients in the low-risk and AFP ≤ 400 ng/mL subgroups.

Figure 2

A. Kaplan–Meier analysis of TTR of patients with HCC with AFP ≤ 400 ng/mL in the training (left) and validation (right) cohorts. B. Kaplan–Meier analysis of TTR of patients with HCC with BCLC stage 0+A in the training (left) and validation (right) cohorts. C. Kaplan–Meier analysis of OS of patients with HCC with AFP ≤ 400 ng/mL in training (left) and validation (right) cohorts. D. Kaplan–Meier analysis of OS of patients with HCC with BCLC stage 0+A in training (left) and validation (right) cohorts.